FOR INFORMATION CONTACT:
Lori Gardner, Senior Director
Communications & Marketing
301.984.9496 ext. 226
For Immediate Release: March 8, 2005
Community Cancer Centers Using Tool to Predict Who Is at Risk for Recurrence of Breast Cancer…but the Assay Has its Limitations
ROCKVILLE, Md.—Recent advances in genomics (the study of genes and their function) are bringing about a revolution in our understanding of the genetic and molecular biology of tumor growth. With this knowledge, scientists hope to develop a tool to predict which patients are at greater risk for developing certain cancers or for having a recurrence after treatment.
Speaking at the Association of Community Cancer Centers (ACCC’s) 31st National Annual Meeting on March 11 in Alexandria, Va., Matthew J.C. Ellis, MB, PhD, FRCP, will discuss the promise of genomics risk assessment for patients with breast cancer.
Community cancer centers are already using an assay (Oncotype DX) to predict the likelihood of breast cancer recurrence among patients with estrogen-positive breast cancer who will be treated with tamoxifen. However, many breast cancer patients receive an anticancer regimen that—instead of tamoxifen— involves aromastase inhibitors as initial or late adjuvant therapy. Aromatase inhibitors are drugs that reduce the levels of estrogen.
The Association of Community Cancer Centers (ACCC) provides a national forum for addressing issues that affect community cancer programs, such as regulatory and legislative issues, measurements of the quality of care, and clinical research. Its unique membership of more than 650 hospital cancer programs and oncology private practices includes all members of the cancer care team: medical and radiation oncologists, surgeons, cancer program administrators and medical directors, oncology nurses, pharmacists, radiation therapists, oncology social workers, and cancer program data managers.